Career Center AES Connect

Abstracts

Nonseizure Outcomes With Cannabidiol (CBD) in Pediatric Versus Adult Patients With Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS): Subgroup Analysis of BECOME, a Caregiver Survey

Abstract number : 3.429
Submission category : 7. Anti-seizure Medications / 7E. Other
Year : 2022
Submission ID : 2232968
Source : www.aesnet.org
Presentation date : 12/5/2022 12:00:00 PM
Published date : Nov 22, 2022, 05:29 AM

Authors :
Tracy Dixon-Salazar, PhD – Lennox-Gastaut Syndrome (LGS) Foundation; Anne Berg, PhD – Northwestern University Feinberg School of Medicine; Mary Anne Meskis, - – Dravet Syndrome Foundation; Sherry Danese, BS, MBA – Outcomes Insights; Timothy Saurer, PhD – Jazz Pharmaceuticals; Ngoc Minh Le, MD – Jazz Pharmaceuticals; M. Scott Perry, MD – Cook Children’s Medical Center

This is a Late Breaking abstract

Rationale: BEhavior, Cognition, and More with Epidiolex® (BECOME) was a global outcomes survey of caregivers of patients with LGS or DS to characterize and quantify the seizure and nonseizure outcomes of the FDA-approved CBD treatment. In the primary analysis, a substantial proportion of caregivers reported improvements in seizure and nonseizure outcomes. Although LGS and DS onset is usually in infancy or early childhood, they are lifelong diseases with symptoms that evolve over time, emphasizing the need to understand the effects of CBD in pediatric vs adult patients. Thus, we compared the seizure and nonseizure outcomes in patients aged < 18 years and ≥18 years. This second abstract reports the nonseizure behavioral and cognitive outcomes.
Anti-seizure Medications